NCT02743741View on ClinicalTrials.gov

Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors

NAActive, not recruitingINTERVENTIONAL
Enrollment

195

Participants

Timeline

Start Date

July 15, 2016

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Neuroendocrine Tumors
Interventions
DRUG

Lutetium-177 Octreotate

Radiopharmaceutical

Trial Locations (4)

Unknown

Juravinski Cancer Centre, Hamilton

London Health Sciences Centre, London

Princess Margaret Cancer Centre, Toronto

Sunnybrook Odette Cancer Center, Toronto

Sponsors
All Listed Sponsors
collaborator

Ozmosis Research Inc.

INDUSTRY

collaborator

Cancer Care Ontario

OTHER

collaborator

Canadian Molecular Imaging Probe Consortium

UNKNOWN

lead

University Health Network, Toronto

OTHER

NCT02743741 - Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors | Biotech Hunter | Biotech Hunter